-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, S/ugRnbQPTxTSfgI2GLMU+a9XPGYxHBQ25C+Ic3RC8OIQlBKcJFn2wKC5EoL0Yl5 lLpdyoweVGZinzPysQTfzw== 0000895345-96-000038.txt : 19960509 0000895345-96-000038.hdr.sgml : 19960509 ACCESSION NUMBER: 0000895345-96-000038 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19960508 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROMEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0000866933 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 133526980 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 033-97722 FILM NUMBER: 96557722 BUSINESS ADDRESS: STREET 1: TWO EXECUTIVE BLVD STE 306 CITY: SUFFERN STATE: NY ZIP: 10901 BUSINESS PHONE: 9143683600 MAIL ADDRESS: STREET 1: TWO EXECUTIVE BLVD STREET 2: SUITE 306 CITY: SUFFERN STATE: NY ZIP: 10901-4164 424B3 1 0108908.01 Filed pursuant to Rule 424(b)(3) Registration Statement No.: 33-97722 Prospectus Supplement No. 4 dated May 6, 1996 (To Prospectus dated December 7, 1995, as supplemented on January 17, February 20 and April 2, 1996) NEUROMEDICAL SYSTEMS, INC. Common Stock (par value $0.0001 per share) On April 30, 1996, the Company announced results for its first quarter ending March 31, 1996. Revenues for the first quarter were $651,000, an increase of 29% from $504,000 for the first quarter of 1995. The Company reported a net loss for the first quarter of 1996 of $6,847,000, or $.24 net loss per share, compared to a net loss of $3,860,000 or $.23 pro forma net loss per share for the first quarter of 1995. The increased net loss, compared to the first quarter of 1995, was due primarily to an increase in marketing and sales expense and the expansion of the administrative and technical infrastructure relating to the commercial launch of the PAPNET Testing System in the United States following clearance by the FDA on November 8, 1995. The Company's efforts during the first quarter were focused on building distribution for PAPNET testing in the United States. During the quarter, PAPNET testing became available through 41 additional laboratories, bringing the total number of sites offering the PAPNET test to 89 by the end of the quarter. During the first quarter, the Company actually scanned pap smears from 55 different laboratories in 25 states. The Company increased its world-wide marketing and sales organization by seven to a total of 41 persons during the quarter. The Company expects to add an additional seven or eight marketing and sales personnel during the second quarter of 1996. -----END PRIVACY-ENHANCED MESSAGE-----